Immune checkpoint inhibitors (ICIs), transformative in oncology, are increasingly implicated in serious cardiac adverse events including myocarditis and pericarditis. These immune-related toxicities pose significant clinical challenges during cancer immunotherapy. Awareness and early detection protocols are critical as immunotherapy use expands. Ongoing research aims to delineate pathogenic mechanisms to mitigate cardiac risks while preserving antitumor efficacy.